logo

For the Inventor, By the Inventor

Lawrence, KS, United States of America

Brian S J Blagg

This inventor holds 25 USPTO granted patents and 4 EPO patents, primarily in Heat Shock Protein Inhibitors. Top assignees: University of Kansas, University of South Florida. Active years: 2011-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Brian S J Blagg. Retrieved from https://idiyas.com/inventor/brian-s-j-blagg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25

% Patents Active = 88.0

 

Average Co-Inventor Count = 2.3

ph-index = 6

Forward Citations = 138(Granted Patents)


Location History:

  • Lawerence, KS (US) (2016)
  • Lawrence, KS (US) (2011 - 2024)
  • Niles, MI (US) (2021 - 2024)

Company Filing History:

goldMedal25 out of 573 
 
University of Kansas
 patents
silverMedal3 out of 1,990 
 
University of South Florida
 patents
where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...
Loading Chart...
Areas of Expertise:
GRP94
HSP90
Inhibitors
Biphenyl Amides
Coumarin
Neuroprotective Agents
Autoimmune Disorders
Dynamic Inhibitors
Modified Sugar Moieties
C-terminal
Selectivity
Therapeutics
25 patents (USPTO):Explore Patents
1. 12269798 - Second generation GRP94-selective inhibitors (2025-04-08),
2. 12024536 - C-terminal HSP90 inhibitors (2024-07-02),
3. 11939291 - GRP94 selective inhibitors and uses thereof (2024-03-26),
4. 11708319 - Biphenyl amides with modified ether groups as HSP90 inhibitors and HSP70 inducers (2023-07-25),
5. 11390640 - C-terminal Hsp90 inhibitors (2022-07-19),
6. 11098008 - Biphenyl amides with modified ether groups as Hsp90 inhibitors and Hsp70 inducers (2021-08-24),
7. 11028041 - Second generation GRP94-selective inhibitors (2021-06-08),
8. 10975030 - Grp94 selective inhibitors and uses thereof (2021-04-13),
9. 10927076 - HSP90B N-terminal isoform-selective inhibitors (2021-02-23),
10. 10882881 - C-terminal Hsp90 inhibitors (2021-01-05),
11. 10745386 - Coumarin based HSP90 inhibitors with urea and ether substituents (2020-08-18),
12. 10689344 - Biphenylamide derivative Hsp90 inhibitors (2020-06-23),
13. 10590157 - C-terminal HSP90 inhibitors (2020-03-17),
14. 10590065 - Biphenyl amides with modified ether groups as HSP90 inhibitors and HSP70 inducers (2020-03-17),
15. 10030041 - C-terminal Hsp90 inhibitors (2018-07-24),

Title: Innovations by Brian S J Blagg: Contributions to Neurodegenerative Disorders and Cancer Treatment

Introduction: Brian S J Blagg, based in Lawrence, KS, is a prolific inventor with a remarkable portfolio of 24 patents. His work focuses on the development of innovative pharmaceutical compounds aimed at treating serious medical conditions, including neurodegenerative disorders and various forms of cancer.

Latest Patents: Among his latest inventions, Blagg has introduced C-terminal HSP90 inhibitors, which are pharmaceutical compositions that contain these compounds. These inhibitors are particularly beneficial in treating and preventing neurodegenerative disorders such as diabetic peripheral neuropathy. Additionally, he has developed GRP94 selective inhibitors, offering potential treatments for metastatic cancer and glaucoma, showcasing his commitment to advancing medical science through innovative therapies.

Career Highlights: Brian S J Blagg has held significant positions in reputable institutions, most notably at the University of Kansas and the University of South Florida. His tenure at these universities has been marked by groundbreaking research and significant contributions to the pharmaceutical field, further solidifying his reputation as a leading inventor in therapeutic innovation.

Collaborations: Throughout his career, Blagg has collaborated with notable colleagues, including Bhaskar Reddy Kusuma and Teather Sundstrom. These partnerships have fostered an environment of shared knowledge and innovation, contributing to the development of effective treatment solutions in the healthcare sector.

Conclusion: Brian S J Blagg's contributions to the field of medical science through his innovative patents reflect his dedication to addressing critical health issues. His work not only enhances our understanding of treatment for neurodegenerative disorders and cancer but also exemplifies the importance of innovation in the pharmaceutical industry. As he continues to push the boundaries of invention, Blagg remains a significant figure in the advancement of therapeutic solutions.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…